Search results
...STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or...
Morningstar· 3 days agoGenentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma ...
...BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE...
Morningstar· 4 days agoFood and Drug Administration (FDA) has approved BLINCYTO® (blinatumomab) for the treatment of adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative ...
Pfizer reports data from Phase II multiple myeloma treatment trial
Clinical Trials Arena via Yahoo Finance· 1 day agoPfizer has announced findings from the Phase II MagnetisMM-3 clinical trial of ELREXFIO...
FDA approves Amgen’s BLINCYTO for acute lymphoblastic leukaemia
Pharmaceutical Technology via Yahoo Finance· 1 day agoThe US Food and Drug Administration (FDA) has approved Amgen’s BLINCYTO (blinatumomab) for...
Rituximab Tied to Increased Infection Risk in RRMS
Medscape· 6 days agoThe B-cell–depleting treatment rituximab was associated with a twofold increased risk for infection in RRMS, regardless of treatment duration or whether the patient had received other DMTs first.
New Clues to Origin of T-Cell Lymphoma After CAR-T Therapy
MedPage Today· 7 days agoOnly one of 724 patients treated with chimeric antigen receptor (CAR) T-cell therapy for B-cell...
Fate Therapeutics stock upgraded by Piper Sandler on autoimmune focus By Investing.com
Investing.com· 1 day agoFate Therapeutics is also advancing its Phase I study of ADR-armed FT522 (CD19 CAR-INK) for patients...
Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study
Zacks via Yahoo Finance· 1 day agoRoche's (RHHBY) Columvi significantly extends survival in patients with relapsed or refractory...
Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto
Morningstar· 4 days agoThe biotechnology company on Friday said the approval is aimed at adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-< ...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 6 days agoIn one study, Pfizer's Seagen-acquired drug, Adcetris, reduced the risk of death by 37% for patients...